NASDAQ:REVB Revelation Biosciences (REVB) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free REVB Stock Alerts $1.91 -0.12 (-5.91%) (As of 05/23/2024 ET) Add Compare Share Share Today's Range$1.86▼$2.0450-Day Range$1.83▼$2.7452-Week Range$1.78▼$36.90Volume27,524 shsAverage Volume261,909 shsMarket Capitalization$3.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Revelation Biosciences alerts: Email Address Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Revelation Biosciences Stock (NASDAQ:REVB)Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.Read More REVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REVB Stock News HeadlinesMay 16, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Revelation Biosciences, Inc. Issued By Roth Capital (NASDAQ:REVB)May 10, 2024 | investorplace.comREVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024May 10, 2024 | businesswire.comRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024March 22, 2024 | businesswire.comRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023March 13, 2024 | finance.yahoo.comRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)March 4, 2024 | finance.yahoo.comRevelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of GeminiFebruary 13, 2024 | finance.yahoo.comRevelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)February 9, 2024 | msn.comRevelation Biosciences Secures $6.2M in Public OfferingFebruary 5, 2024 | finance.yahoo.comRevelation Biosciences Inc. Announces Closing of $6.2 Million Public OfferingFebruary 2, 2024 | marketwatch.comRevelation Biosciences Shares Slide Premarket on Public OfferingFebruary 1, 2024 | msn.comRevelation Biosciences to raise ~$6.2M through public offering of sharesFebruary 1, 2024 | investorplace.comWhy Is Revelation Biosciences (REVB) Stock Down 62% Today?January 30, 2024 | finance.yahoo.comRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)January 29, 2024 | seekingalpha.comFATE, NEXI and INBS among mid-day moversJanuary 26, 2024 | finance.yahoo.comREVB Continues March to TrialsJanuary 23, 2024 | finance.yahoo.comRevelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024November 22, 2023 | morningstar.comRevelation Biosciences Inc Ordinary Shares REVBNovember 14, 2023 | finance.yahoo.comREVB Releases Earnings and Prepares for TrialsNovember 14, 2023 | msn.comRevelation Biosciences GAAP EPS of -$0.42November 13, 2023 | finance.yahoo.comRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023October 12, 2023 | finance.yahoo.comGemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical StudiesOctober 4, 2023 | finance.yahoo.comRevelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities ConferenceOctober 2, 2023 | finance.yahoo.comRevelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of DirectorsAugust 14, 2023 | finance.yahoo.comREVB Reports Solid Balance Sheet and Remains on TrackAugust 11, 2023 | finance.yahoo.comRevelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023See More Headlines Receive REVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today5/23/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:REVB CUSIPN/A CIK1810560 Webwww.revbiosciences.com Phone650-800-3717FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($30.9105) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.56% Return on Assets-62.04% Debt Debt-to-Equity RatioN/A Current Ratio2.80 Quick Ratio2.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.80 per share Price / Book0.33Miscellaneous Outstanding Shares1,630,000Free Float1,629,000Market Cap$3.11 million OptionableNot Optionable Beta0.17 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. James M. Rolke (Age 55)CEO & Director Comp: $649.25kMr. Chester Stanley Zygmont III (Age 44)CFO & Corporate Secretary Comp: $479.14kMs. Sandra VedrickVice President of Human Resources & Investor RelationsMs. Carol OdleSenior Director of Clinical ProjectsKey CompetitorsAyala PharmaceuticalsNASDAQ:ADXSZyVersa TherapeuticsNASDAQ:ZVSACyclacel PharmaceuticalsNASDAQ:CYCCLongeveronNASDAQ:LGVN60 Degrees PharmaceuticalsNASDAQ:SXTPView All CompetitorsInsidersGeorge F. TidmarshSold 925 sharesTotal: $14,430.00 ($15.60/share)George F TidmarshSold 365 sharesTotal: $7,227.00 ($19.80/share)George F TidmarshSold 47 sharesTotal: $972.90 ($20.70/share)George F TidmarshSold 133 sharesTotal: $2,952.60 ($22.20/share)George F TidmarshSold 400 sharesTotal: $9,000.00 ($22.50/share)View All Insider Transactions REVB Stock Analysis - Frequently Asked Questions How have REVB shares performed in 2024? Revelation Biosciences' stock was trading at $15.0210 at the beginning of the year. Since then, REVB shares have decreased by 87.3% and is now trading at $1.91. View the best growth stocks for 2024 here. When is Revelation Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our REVB earnings forecast. How were Revelation Biosciences' earnings last quarter? Revelation Biosciences, Inc. (NASDAQ:REVB) posted its quarterly earnings data on Friday, March, 22nd. The company reported ($8.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($10.94) by $2.61. When did Revelation Biosciences' stock split? Shares of Revelation Biosciences reverse split on the morning of Thursday, January 25th 2024. The 1-30 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Revelation Biosciences? Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:REVB) was last updated on 5/24/2024 by MarketBeat.com Staff From Our PartnersBiden replacement revealed?Paradigm PressUrgent Nvidia WarningAltimetry**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
